Non-
alcoholic steatohepatitis (NASH) has become the most important reason of
liver disease around the world and is predisposed to further progression to
cirrhosis and
hepatocellular carcinoma.
Ginsenoside Rk3 has been reported to have a plenty of biological activities, including anti-apoptotic, anti-
anemia, and protective effects against
acute kidney injury. However, whether
ginsenoside Rk3 can improve NASH has not been reported yet. Therefore, the purpose of this study is to investigate the protective effect of
ginsenoside Rk3 against NASH and its mechanism of action. C57BL/6 mice were treated with different dosages of
ginsenoside Rk3 after being established as a NASH model. Our results showed that Rk3 administration significantly improved liver
inflammation,
lipid deposition, and
fibrosis caused by a high-fat-high-
cholesterol (HFHC) diet and CCl4 injection in mice. Notably,
ginsenoside Rk3 was discovered significantly to inhibit the PI3K/AKT signaling pathway. Additionally, treatment with
ginsenoside Rk3 remarkably amended the abundance of
short-chain fatty acids. These changes were associated with beneficial variations to the variety and composition of the intestinal microbiota. In conclusion,
ginsenoside Rk3 ameliorates hepatic non-alcoholic
lipid inflammation and triggers changes in the beneficial intestinal flora, helping to reveal host-microbe interactions. The outcomes of this study indicate that
ginsenoside Rk3 is a promising drug candidate for the treatment of NASH.